Literature DB >> 24565585

Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.

Eamon M Berge1, Robert C Doebele2.   

Abstract

The diagnostic testing, treatment and prognosis of non-small cell lung cancer (NSCLC) has undergone a paradigm shift since the discovery of sensitizing mutations in the epidermal growth factor receptor (EGFR) gene in a subset of NSCLC patients. Several additional oncogenic mutations, including gene fusions and amplifications, have since been discovered, with a number of drugs that target each specific oncogene. This review focuses on oncogenes in NSCLC other than EGFR and their companion "targeted therapies." Particular emphasis is placed on the role of ALK, ROS1, RET, MET, BRAF, and HER2 in NSCLC.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24565585      PMCID： PMC4159759          DOI： 10.1053/j.seminoncol.2013.12.006

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  123 in total

1.  Missense mutations of the BRAF gene in human lung adenocarcinoma.

Authors:  Katsuhiko Naoki; Tzu-Hsiu Chen; William G Richards; David J Sugarbaker; Matthew Meyerson
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

2.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

Authors:  Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

3.  Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.

Authors:  Siu T Yuen; Helen Davies; Tsun L Chan; Judy W Ho; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Wendy W Tsui; Annie S Chan; P Andrew Futreal; Michael R Stratton; Richard Wooster; Suet Y Leung
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

4.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

Review 5.  Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma.

Authors:  Jeffery L Kutok; Jon C Aster
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

6.  Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.

Authors:  Alex A Adjei; Ann Mauer; Laura Bruzek; Randolph S Marks; Shauna Hillman; Susan Geyer; Lorelei J Hanson; John J Wright; Charles Erlichman; Scott H Kaufmann; Everett E Vokes
Journal:  J Clin Oncol       Date:  2003-05-01       Impact factor: 44.544

7.  Cancer. Addiction to oncogenes--the Achilles heal of cancer.

Authors:  I Bernard Weinstein
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

8.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

10.  Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas.

Authors:  F R Hirsch; M Varella-Garcia; W A Franklin; R Veve; L Chen; B Helfrich; C Zeng; A Baron; P A Bunn
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640
View more
  33 in total

1.  JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.

Authors:  Xudong Shen; Zhixiang Zhuang; Yusong Zhang; Zhigang Chen; Liqin Shen; Wangyang Pu; Lei Chen; Zhonghua Xu
Journal:  Tumour Biol       Date:  2015-04-16

2.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Authors:  Ferdinandos Skoulidis; Lauren A Byers; Lixia Diao; Vassiliki A Papadimitrakopoulou; Pan Tong; Julie Izzo; Carmen Behrens; Humam Kadara; Edwin R Parra; Jaime Rodriguez Canales; Jianjun Zhang; Uma Giri; Jayanthi Gudikote; Maria A Cortez; Chao Yang; Youhong Fan; Michael Peyton; Luc Girard; Kevin R Coombes; Carlo Toniatti; Timothy P Heffernan; Murim Choi; Garrett M Frampton; Vincent Miller; John N Weinstein; Roy S Herbst; Kwok-Kin Wong; Jianhua Zhang; Padmanee Sharma; Gordon B Mills; Waun K Hong; John D Minna; James P Allison; Andrew Futreal; Jing Wang; Ignacio I Wistuba; John V Heymach
Journal:  Cancer Discov       Date:  2015-06-11       Impact factor: 39.397

3.  RET fusion as a novel driver of medullary thyroid carcinoma.

Authors:  Elizabeth G Grubbs; Patrick Kwok-Shing Ng; Jacquelin Bui; Naifa L Busaidy; Ken Chen; Jeffrey E Lee; Xinyan Lu; Hengyu Lu; Funda Meric-Bernstam; Gordon B Mills; Gary Palmer; Nancy D Perrier; Kenneth L Scott; Kenna R Shaw; Steven G Waguespack; Michelle D Williams; Roman Yelensky; Gilbert J Cote
Journal:  J Clin Endocrinol Metab       Date:  2014-12-29       Impact factor: 5.958

Review 4.  Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer.

Authors:  Mukesh Kumar; Vinicius Ernani; Taofeek K Owonikoko
Journal:  Mol Aspects Med       Date:  2015-07-14

5.  Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.

Authors:  Sarah K Nelson-Taylor; Anh T Le; Minjae Yoo; Laura Schubert; Katie M Mishall; Andrea Doak; Marileila Varella-Garcia; Aik-Choon Tan; Robert C Doebele
Journal:  Mol Cancer Ther       Date:  2017-05-12       Impact factor: 6.261

6.  Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.

Authors:  Zhenya Tang; Jianjun Zhang; Xinyan Lu; Wei Wang; Hui Chen; Melissa K Robinson; Joanne Cheng; Guilin Tang; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2017-09-15       Impact factor: 7.842

7.  Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.

Authors:  Frank Hilberg; Ulrike Tontsch-Grunt; Anke Baum; Anh T Le; Robert C Doebele; Simone Lieb; Davide Gianni; Tilman Voss; Pilar Garin-Chesa; Christian Haslinger; Norbert Kraut
Journal:  J Pharmacol Exp Ther       Date:  2017-12-20       Impact factor: 4.030

8.  The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis.

Authors:  Hengrui Liang; Zhenkui Pan; Wei Wang; Chengye Guo; Difei Chen; Jianrong Zhang; Yiyin Zhang; Shiyan Tang; Jianxing He; Wenhua Liang
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

9.  The association between human papillomavirus presence and epidermal growth factor receptor mutations in Asian patients with non-small cell lung cancer.

Authors:  Hengrui Liang; Zhenkui Pan; Xiuyu Cai; Wei Wang; Chengye Guo; Jiaxi He; Yuehan Chen; Zhichao Liu; Bo Wang; Jianxing He; Wenhua Liang
Journal:  Transl Lung Cancer Res       Date:  2018-06

10.  Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.

Authors:  Matteo Menotti; Cristina Mastini; Claudia Voena; Filomena Di Giacomo; Dario Livio Longo; Barbara Castella; Maria Elena Boggio Merlo; Chiara Ambrogio; Qi Wang; Valerio Giacomo Minero; Teresa Poggio; Cinzia Martinengo; Lucia D'Amico; Elena Panizza; Luca Mologni; Federica Cavallo; Fiorella Altruda; Mohit Butaney; Marzia Capelletti; Giorgio Inghirami; Pasi A Jänne; Roberto Chiarle
Journal:  Cancer Immunol Res       Date:  2015-09-29       Impact factor: 11.151
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.